Fig. 3From: A study of concurrent chemoradiotherapy with weekly docetaxel and cisplatin for advanced esophageal squamous cell carcinoma with T4 and/or M1 lymph node metastasis or locoregional recurrenceOverall survival (a), progression-free survival (b) and locoregional control (c) according to enrolled group (newly diagnosed vs. recurrent). OS, overall survival; PFS, progression-free survivalBack to article page